GPR84 and Hepatic fibrosis: Importantly, liver fibrosis was reduced in the GPR84 antagonist- or selonsertib-treated groups, as assessed by quantification of Sirius-Red-stained liver sections and hepatic hydroxyproline content (Figure 4D–E).